Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites
- PMID: 36016680
- PMCID: PMC9398791
- DOI: 10.1155/2022/3050199
Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites
Retraction in
-
Retracted: Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites.Evid Based Complement Alternat Med. 2023 Jul 19;2023:9871636. doi: 10.1155/2023/9871636. eCollection 2023. Evid Based Complement Alternat Med. 2023. PMID: 37501834 Free PMC article.
Abstract
The prognosis of multiple myeloma (MM) patients was poor in white-American patients as compared to black-American patients. This study aimed to predict the death of MM patients in whites based on the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. A total of 28,912 white MM patients were included in this study. Data were randomly divided into a training set and a test set (7 : 3). The random forest and 5-fold cross-validation were used for developing a prediction model. The performance of the model was determined by calculating the area under the curve (AUC) with 95% confidence interval (CI). MM patients in the death group had older age, higher proportion of tumor distant metastasis, bone marrow as the disease site, receiving radiotherapy, and lower proportion of receiving chemotherapy than that in the survival group (all P < 0.001). The AUC of the random forest model in the training set and testing set was 0.741 (95% CI, 0.740-0.741) and 0.703 (95% CI, 0.703-0.704), respectively. In addition, the AUC of the age-based model was 0.688 (95% CI, 0.688-0.689) in the testing set. The results of the DeLong test indicated that the random forest model had better predictive effect than the age-based model (Z = 7.023, P < 0.001). Further validation was performed based on age and marital status. The results presented that the random forest model was robust in different age and marital status. The random forest model had a good performance to predict the death risk of MM patients in whites.
Copyright © 2022 Jian Tao et al.
Conflict of interest statement
The authors declare no conflicts of interest regarding the publication of this article.
Figures




Similar articles
-
The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.BMC Med Inform Decis Mak. 2023 Apr 21;23(1):74. doi: 10.1186/s12911-023-02166-8. BMC Med Inform Decis Mak. 2023. PMID: 37085843 Free PMC article.
-
Establishment and validation of the predictive model for the in-hospital death in patients with sepsis.Am J Infect Control. 2021 Dec;49(12):1515-1521. doi: 10.1016/j.ajic.2021.07.010. Epub 2021 Jul 25. Am J Infect Control. 2021. PMID: 34314757
-
Development and Validation of the Random Forest Model via Combining CT-PET Image Features and Demographic Data for Distant Metastases among Lung Cancer Patients.J Healthc Eng. 2022 Dec 13;2022:7793533. doi: 10.1155/2022/7793533. eCollection 2022. J Healthc Eng. 2022. PMID: 36561373 Free PMC article.
-
Analysis of risk factors for lymph node metastasis and prognosis study in patients with early gastric cancer: A SEER data-based study.Front Oncol. 2023 Mar 17;13:1062142. doi: 10.3389/fonc.2023.1062142. eCollection 2023. Front Oncol. 2023. PMID: 37007147 Free PMC article.
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
Cited by
-
Retracted: Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites.Evid Based Complement Alternat Med. 2023 Jul 19;2023:9871636. doi: 10.1155/2023/9871636. eCollection 2023. Evid Based Complement Alternat Med. 2023. PMID: 37501834 Free PMC article.
References
-
- Moreau P., San Miguel J., Sonneveld P., et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology . 2013;24(6):vi133–7. - PubMed
-
- Terpos E., Zamagni E., Lentzsch S., et al. Treatment of multiple myeloma-related bone disease: recommendations from the bone working group of the international myeloma working group. The Lancet Oncology . 2021;22:e119–30. - PubMed
-
- Howlader N. A., Noone A. M. SEER Cancer Statistics Review . Bethesda, MA, USA: National Cancer Institute; 2017.
Publication types
LinkOut - more resources
Full Text Sources